Enfusion (NYSE:ENFN) Stock Price Up 4.2% - Time to Buy?

Enfusion, Inc. (NYSE:ENFN - Get Free Report)'s share price was up 4.2% on Monday . The stock traded as high as $10.59 and last traded at $10.51. Approximately 470,309 shares were traded during mid-day trading, an increase of 20% from the average daily volume of 391,553 shares. The stock had previously closed at $10.09.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ENFN shares. Stifel Nicolaus upped their price target on shares of Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. Piper Sandler increased their target price on Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a report on Monday, December 23rd. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, Enfusion currently has an average rating of "Hold" and a consensus price target of $10.25.

Enfusion Price Performance

The firm's 50 day moving average price is $9.89 and its 200 day moving average price is $9.08. The stock has a market capitalization of $1.35 billion, a P/E ratio of 261.82, a P/E/G ratio of 3.98 and a beta of 0.97.

Insider Buying and Selling at Enfusion

In other news, CFO Bradley Herring sold 24,443 shares of the business's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $10.61, for a total transaction of $259,340.23. Following the transaction, the chief financial officer now directly owns 270,503 shares of the company's stock, valued at approximately $2,870,036.83. The trade was a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Neal Pawar sold 21,801 shares of the firm's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the sale, the chief operating officer now directly owns 1,143,544 shares of the company's stock, valued at $11,469,746.32. The trade was a 1.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 46,918 shares of company stock valued at $484,037 in the last 90 days. Insiders own 36.44% of the company's stock.

Hedge Funds Weigh In On Enfusion

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its position in Enfusion by 7.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company's stock valued at $9,770,000 after acquiring an additional 70,367 shares in the last quarter. Wellington Management Group LLP grew its stake in Enfusion by 6.7% in the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company's stock worth $9,265,000 after purchasing an additional 61,032 shares during the period. State Street Corp lifted its position in Enfusion by 2.3% during the third quarter. State Street Corp now owns 952,895 shares of the company's stock valued at $9,043,000 after buying an additional 21,729 shares during the period. Impax Asset Management Group plc boosted its holdings in shares of Enfusion by 25.4% during the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company's stock valued at $6,424,000 after buying an additional 136,948 shares in the last quarter. Finally, Scalar Gauge Management LLC boosted its holdings in shares of Enfusion by 21.8% during the 2nd quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company's stock valued at $5,227,000 after buying an additional 110,000 shares in the last quarter. Hedge funds and other institutional investors own 81.05% of the company's stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.